Saltar al contenido
Merck

R3530

Rifabutin

>98% (HPLC), powder, antibiotic

Sinónimos:

Ansamycin, Ansatipine (Farmitalia), LM-427, Mycobutin (Farmitalia)

Iniciar sesión para ver los precios por organización y contrato.

Seleccione un Tamaño

5 MG

US$ 147,00

25 MG

US$ 582,00

US$ 147,00

PRECIOS SIN IMPUESTOS NACIONALES

Comprobar disponibilidad del carrito

Solicite una orden a granel

Acerca de este artículo

Fórmula empírica (notación de Hill):
C46H62N4O11
Número CAS:
Peso molecular:
847.00
UNSPSC Code:
12352200
NACRES:
NA.77

Saltar a

Servicio técnico
¿Necesita ayuda? Nuestro equipo de científicos experimentados está aquí para ayudarle.
Permítanos ayudarle

Nombre del producto

Rifabutin, >98% (HPLC), powder

SMILES string

[N+H]1(CCC2(NC3=C4NC(=O)\C(=C/C=C/[C@@H]([C@@H]([C@H]([C@H]([C@H]([C@@H]([C@@H]([C@H](\C=C\O[C@]5(Oc6c(c(c(c(c6C)[O-])C4=O)C3=N2)C5=O)C)OC)C)OC(=O)C)C)O)C)O)C)\C)CC1)CC(C)C

InChI

1S/C46H62N4O11/c1-22(2)21-50-18-16-46(17-19-50)48-34-31-32-39(54)28(8)42-33(31)43(56)45(10,61-42)59-20-15-30(58-11)25(5)41(60-29(9)51)27(7)38(53)26(6)37(52)23(3)13-12-14-24(4)44(57)47-36(40(32)55)35(34)49-46/h12-15,20,22-23,25-27,30,37-38,41,49,52-54H,16-19,21H2,1-11H3,(H,47,57)/b13-12+,20-15+,24-14-/t23-,25+,26+,27+,30-,37-,38+,41+,45-/m0/s1

InChI key

ATEBXHFBFRCZMA-VXTBVIBXSA-N

assay

>98% (HPLC)

form

powder

storage condition

protect from light

solubility

DMSO: >5 mg/mL

antibiotic activity spectrum

neoplastics

mode of action

enzyme | inhibits

originator

Johnson & Johnson

shipped in

wet ice

storage temp.

−20°C

Quality Level

¿Está buscando productos similares? Visita Guía de comparación de productos

Categorías relacionadas

Comparar elementos similares

Ver comparación completa

Mostrar Diferencias

1 of 4

Este artículo
1603800Y0000149PHR2611
USP

USP

1603800

Rifabutin

vibrant-m

Y0000149

Rifabutin

form

powder

form

-

form

-

form

solid

assay

>98% (HPLC)

assay

-

assay

-

assay

-

Quality Level

100

Quality Level

-

Quality Level

-

Quality Level

300

storage temp.

−20°C

storage temp.

-

storage temp.

2-8°C

storage temp.

-10 to -25°C

storage condition

protect from light

storage condition

-

storage condition

-

storage condition

-

solubility

DMSO: >5 mg/mL

solubility

-

solubility

-

solubility

-

Biochem/physiol Actions

Rifabutin is an antibiotic; antitumor. Rifabutin interferes with HSP-90 molecular chaperone, enhances ubiquitination and protein degradation, and inactivates bacterial RNA polymerase.
Rifabutin is an antibiotic; antitumor.

Features and Benefits

This compound was developed by Johnson & Johnson. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Clase de almacenamiento

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)


Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number

¿No ve la versión correcta?

Si necesita una versión concreta, puede buscar un certificado específico por el número de lote.

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Jakko van Ingen et al.
American journal of respiratory and critical care medicine, 186(6), 559-565 (2012-06-30)
Currently recommended multidrug treatment regimens for Mycobacterium avium complex (MAC) lung disease yield limited cure rates. This results, in part, from incomplete understanding of the pharmacokinetics and pharmacodynamics of the drugs. To study pharmacokinetics, pharmacodynamics, and drug interactions of multidrug
C Y Tay et al.
Alimentary pharmacology & therapeutics, 36(11-12), 1076-1083 (2012-10-18)
Helicobacter pylori eradication rates with standard triple therapy are declining worldwide. The optimal management of H. pylori is evolving and new treatment combinations for antibiotic resistant H. pylori strains are required, especially for patients with penicillin allergy. To review the
Kelly E Dooley et al.
Journal of acquired immune deficiency syndromes (1999), 62(1), 21-27 (2012-10-19)
Cotreatment of tuberculosis (TB) and HIV among coinfected patients is now the standard of care. Rifampin (RIF) is a standard part of TB treatment but is a potent inducer of drug metabolizing enzymes. This study evaluated the effect of RIF
J P Gisbert et al.
Alimentary pharmacology & therapeutics, 35(8), 941-947 (2012-03-01)
In some cases, Helicobacter pylori infection persists even after three eradication treatments. To evaluate the efficacy of an empirical fourth-line rescue regimen with rifabutin in patients with three eradication failures. Multicentre, prospective study. In whom the following three treatments had
Matthew D Hickey et al.
Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 19(4), 457-461 (2013-03-26)
Latent tuberculosis infection is an important problem for solid organ transplant recipients because of the frequency of its occurrence and its potential for reactivation. Because of the high mortality rate associated with active tuberculosis infections in transplant recipients, guidelines from

Artículos

Bioactive small molecules for immune system signaling target identification/validation and antibiotics, antivirals, and antifungals offered.

Questions

Reviews

No rating value

Active Filters

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico